首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1425122

全球體學實驗室服務市場：預測（2024-2029）

Omics Lab Services Market - Forecasts from 2024 to 2029

出版日期: 2024年01月25日 | 出版商:

Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2022 年，體學實驗室服務市場價值將達到 988.42 億美元，預測期內複合年成長率為 15.17%。

以-omics結尾的生物科學研究，如基因組學、轉錄組學、蛋白質組學、代謝組學等，稱為體學。基因組研究探索基因組的結構、功能、演化和作圖，重點是在酵素和信使分子的幫助下控制蛋白質生產的基因的表徵和定量。除了化學特性之外，體學還包括每個 RNA 分子的數量和濃度。

體學技術在癌症研究的優勢

基因組、轉錄、蛋白質組和代謝水平的複雜相互作用參與癌症發病機制。由於綜合多組體學分析，我們對腫瘤複雜生物學的理解，包括免疫逃脫、腫瘤發展、腫瘤異質性、腫瘤微環境和抗治療性，已大大增加。體學技術有可能對癌症研究極為有益，因為它們提供了前所未有的機會在多個病理和分子層面上說明癌症生物學。匯集多個組體學的資料是了解致癌機制的重要第一步。高通量技術的進步使得多種體學方法，包括基因組學、表觀基因、轉錄組學、蛋白質組學和代謝組學，可用於分析不同但互補的生物層。

基因組學和巨量資料分析的創新

隨著醫療保健巨量資料領域的快速擴張，基於案例的研究正在被廣泛的資料驅動研究所取代。由於巨量資料依賴新資料標準、技術和相關研究的發展，因此巨量資料應用的未來發展在當前的醫療革命中具有可預測的潛力。極其龐大且快速擴展的生物體學資料（基因組學、蛋白質組學、轉錄組學、代謝組學、醣質學等）和臨床資料的處理和解釋提供了重大障礙和可能性，而這些數據為解決問題帶來了新的運算閘道器。

磊晶的日益普及

在預測期內，磊晶類別預計將以最快的速度發展。提供體學實驗室服務的公司正致力於使其產品和服務多樣化，以吸引體學實驗室服務市場。例如，2022 年 1 月，Eisbach Bio GmbH 和德克薩斯大學MD 安德森癌症中心宣布了一項策略，共同識別和創建精準腫瘤療法，針對腫瘤基因組進化所必需的合成命運引擎。我們已經開始了研究合作夥伴關係。透過此次合作，艾斯巴赫和 MD 安德森癌症中心的治療發現部門將結合最先進的發現平台和變構測定技術，特異性抑制具有特定基因改變的癌症的基因組複製和 DNA 修復。那將

轉錄組學的普及

與基因組學領域相比，轉錄組學在單細胞轉錄組學分析中的高利用率說明了體學實驗室服務市場的擴張。雷射捕獲晶粒（LCM）等自動化定序方法可以滿足生物材料核酸定序的需求，並正在推動空間基因組學產業的發展。保存遺傳或地理資料以供以後使用的尖端定序技術的發展也受到對組織異質性更深入了解的啟發。預計這一因素將在整個預期期間刺激體學實驗室服務市場的擴張。

政府對基因組學計劃的投資

據澳洲政府稱，醫學遺傳學研究已從基因組學健康未來使命獲得 5.01 億美元。基因組學有可能徹底改變臨床醫學。基因組學健康未來使命以已完成的研究為基礎，旨在展示遺傳學和相關技術如何支持患者和衛生系統。隨著基因組學的使用變得更加廣泛，客製化和改善疾病管理的機會將會增加。受人類基因計劃的啟發，生物技術系 (DBT) 於 2020 年 1 月 3 日啟動了雄心勃勃的「印度基因計劃」(GIP)。為了創建參考基因組，GIP 正在從全國各地的印度居民收集 10,000 個基因樣本。

北美組體學實驗室服務市場預計將穩定成長

北美體學實驗室服務市場的擴張預計將受到臨床研究中基因檢測日益成長的需求的推動，包括針對糖尿病和癌症等疾病的個人化醫療。例如，根據美國疾病管制與預防中心的數據，美國癌症協會利用中央癌症登記處的發病率資料和國家健康統計中心的死亡率資料估計了美國新發癌症病例和死亡人數每年估計並彙編有關基於人群的癌症發生率和結果的最新資訊。到 2023 年，美國可能將有 609,820 例癌症相關死亡病例和 1,958,310 例新癌症病例。

本公司提供的體學實驗室服務

安捷倫：靈活的蛋白質體學分析工具，可最大限度地提高通量和靈敏度。全面的代謝組學分析解決方案可促進您的運作。創新的脂質組學分析工具使複雜的程序變得更加簡單。
Cerba Research：Cerba Research 為臨床前、轉化和臨床研究計劃提供組織組體學服務。這些高度適應性的系統提供了對完整組織、整體或空間、感興趣區域和組織切片上特定細胞群中的蛋白質和轉錄本的定量研究。 nCounter(R) 和 GeoMx(R) 奈米串平台將安裝在實驗室中，為每個請求提供最合適的資料集。

A biological science branch of study that ends in -omics, such as genomics, transcriptomics, proteomics, or metabolomics, is referred to as an omics. Genomic research focuses on characterizing and quantifying genes, which regulate the creation of proteins with the aid of enzymes and messenger molecules, and explores the structure, function, evolution, and mapping of genomes. In addition to the chemical identities, it also contains the quantity or concentration of each RNA molecule.

Benefits of omics technologies in cancer research

Complex interactions at the genomic, transcriptional, proteomic, and metabolic levels play a role in the etiology of cancer. The comprehension of the intricate biology of tumors, including immune evasion, tumor development, tumor heterogeneity, the tumor microenvironment, and treatment resistance, has considerably increased as a result of integrative multi-omics analysis. Since they provide an unprecedented chance to describe cancer biology at several pathological and molecular levels, omics technologies have the potential to be extremely beneficial to cancer research. Pooling data from several omics is an essential first step to understanding the mechanisms behind oncogenesis. With high-throughput technology advancements, a variety of omics methods, including genomes, epigenomics, transcriptomics, proteomics, and metabolomics, are accessible to analyze diverse yet complementary biological layers.

Innovations in Genomics and Big Data Analytics

Case-based studies are being replaced with extensive, data-driven research due to the rapidly expanding field of big data in health care. Big data applications' future development has predictable potential in the present healthcare revolution since big data is dependent on the development of new data standards, technology, and related research. The processing and interpretation of very vast, quickly expanding sets of biological omics data (genomics, proteomics, transcriptomics, metabolomics, glycomics, etc.) and clinical data provide significant obstacles as well as possibilities, and they also bring up new computational gateways to solve these problems.

Growing popularity in epigenetics

Throughout the projection period, the epigenetics category is anticipated to develop at the quickest rate. Businesses providing omics lab services are focusing on diversifying their product and service offerings to appeal to this omics lab services market. For instance, in January 2022, Eisbach Bio GmbH and the University of Texas MD Anderson Cancer Centre launched a strategic research partnership to collaboratively identify and create precision oncology therapies that target synthetic fatal engines crucial to tumor genome evolution. Through this partnership, Eisbach and MD Anderson's Therapeutics Discovery division will combine their cutting-edge discovery platforms and allosteric assay technologies to develop drugs that specifically disrupt genome replication and DNA repair in cancers carrying specific genetic alterations.

Rising adoption of transcriptomics

The higher usage of transcriptomics for single-cell transcriptomics analysis compared to the genomics sector accounts for the omics lab services market expansion. Automated sequencing methods like the laser capture microdissection technique (LCM) have been able to meet the demand for nucleic acid sequencing of biological materials, which has fueled the growth of the spatial genomics industry. The development of cutting-edge sequencing technologies to save genetic or geographical data for later use has also been inspired by a deeper knowledge of tissue heterogeneity. It is projected that this element would stimulate omics lab services market expansion throughout the anticipated period.

Government investments in genomics projects

According to the Australian Government, research in genetic medicine is receiving $500.1 million from the Genomics Health Futures Mission. The science of genomics has the potential to revolutionize clinical medicine. To show how genetics and associated technologies assist patients and the healthcare system, the Genetics Health Futures Mission will expand on already completed research. Opportunities to customize and improve illness management will grow as genomics usage becomes more pervasive. The Department of Biotechnology (DBT) launched the ambitious "Genome India Project" (GIP) on January 3rd, 2020, drawing inspiration from the Human Genome Project. To create a reference genome, the GIP seeks to gather 10,000 genetic samples from Indian residents throughout the country.

In North America, it is projected that the omics lab services market will grow steadily.

Omics lab services market expansion in North America is anticipated to be fueled by the growing demand for genetic testing in clinical studies including personalized healthcare for diseases like diabetes and cancer. For instance, according to the Centers for Disease Control and Prevention, using incidence data from central cancer registries and mortality data from the National Centre for Health Statistics, the American Cancer Society estimates the number of new cancer cases and deaths in the United States each year and compiles the most recent information on population-based cancer occurrence and outcomes. In 2023, there will likely be 609,820 cancer-related fatalities and 1,958,310 new cases of cancer in the United States.

Omics Lab Services offered by Companies

Agilent, Flexible proteomics analysis tools for the maximum throughput and sensitivity. Solutions for comprehensive metabolomics analysis advance operations. Innovative lipidomics analysis tools make complex procedures simpler.
Cerba Research, Tissue omics services are provided by Cerba Research for pre-clinical, translational, and clinical research projects.These adaptable systems provide the quantitative study of proteins and transcripts in complete tissue, either in bulk or spatially in regions of interest and particular cell populations on tissue slices. The nCounter® and GeoMx® Nanostring platforms are installed in labs to deliver the most pertinent datasets for each request.

Market Key Developments

In September 2023, MGI, a firm dedicated to creating the fundamental tools and technology to drive life science, unveiled the DCS Lab Initiative to support expansive leading multi-omics laboratories and advance vital scholarly endeavors. As part of the program, the business will make products based on DNBSEQ technology available to chosen research organizations worldwide for a variety of applications, including DNA sequencing, cell omics, and spatial omics.
In April 2023, a deal was reached between Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, and Fulgent Genetics, a technology-based company with a reputable clinical diagnostics and therapeutic development business.

Segmentation:

By Services

Genomics
Proteomics
Transcriptomic
Metabolomics
Epigenetics

By Product

One-Off
Repeat
Continuous

By End-Use

Hardware Equipment
Testing/Lab
Analytics

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. OMICS LAB SERVICES MARKET, BY SERVICES

5.1. Introduction
5.2. Genomics
5.3. Proteomics
5.4. Transcriptomic
5.5. Metabolomics
5.6. Epigenetics

6. OMICS LAB SERVICES MARKET, BY PRODUCT

6.1. Introduction
6.2. One-Off
6.3. Repeat
6.4. Continuous

7. OMICS LAB SERVICES MARKET, BY END-USE

7.1. Introduction
7.2. Hardware Equipment
7.3. Testing/Lab
7.4. Analytics

8. OMICS LAB SERVICES MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others